LINQ MANAGEMENT GMBH

Their core work

LINQ Management GmbH is a Berlin-based SME that operates at the intersection of biomedical data management and health research infrastructure. Their H2020 participation centers on two distinct but complementary projects: building federated, interoperable cancer genomics networks (EUCANCan) and contributing to the Human Cell Atlas of the Pancreas (ESPACE). Their work involves making complex biological data usable across institutional and national boundaries — standardizing formats, aligning data-sharing protocols, and enabling harmonized analysis of genomic and cellular datasets. As a "management" company in scientific consortia, they likely contribute project coordination, data governance, or technology integration capacity rather than wet-lab research.

What they specialise in

How they've shifted over time

With only two projects starting in 2019 and 2020, there is no meaningful long-term evolution to trace — both projects launched within a year of each other and represent concurrent, not sequential, commitments. What the data does show is a deliberate dual focus from the outset: one project in large-scale cancer genomics infrastructure, one in precision cellular mapping of a specific organ. The absence of keywords for the more recent project period (ESPACE) makes it impossible to characterize a clear shift in direction.

With only two overlapping projects and no coordinator roles, LINQ's trajectory remains unclear — they appear to be building a track record in health data infrastructure, but there is insufficient evidence to predict whether their next move will be deeper genomics specialization, broader cell atlas work, or a pivot to health data governance consultancy.

How they like to work

LINQ has participated exclusively as a consortium partner, never as a project coordinator, across both of their H2020 projects. Their 26 unique partners across 8 countries for just two projects indicates participation in large, multi-institutional consortia — typical of RIA health infrastructure projects — rather than small focused collaborations. This profile suggests they are brought in as a specialist contributor or management support function within bigger scientific networks, not as a consortium-builder themselves.

LINQ has connected with 26 unique consortium partners across 8 countries through two projects, implying roughly 13 partners per project on average — consistent with large pan-European RIA consortia. Their geographic reach spans multiple EU member states, though no dominant single-country clustering is evident from the available data.

What sets them apart

LINQ's combination of a management company structure with deep participation in technically demanding health data infrastructure projects suggests they offer a rare bridge between scientific research consortia and project governance or data management expertise. For a consortium builder, this means they may be able to contribute not just technical knowledge but the organizational capacity to coordinate complex multi-partner data workflows. However, with only two projects on record, this positioning should be verified directly with the organization before making collaboration decisions.

Highlights from their portfolio

• EUCANCan
  The larger and more keyword-rich of LINQ's two projects, EUCANCan addresses one of European health research's core bottlenecks — making cancer genomic data comparable and analyzable across national borders — making it a flagship data infrastructure initiative.
• ESPACE
  Contributing to the Human Cell Atlas of the Pancreas places LINQ at the frontier of single-cell biology data generation, a field with significant implications for diabetes and pancreatic cancer research.